Genetic studies have provided increasing evidence that ceramide homeostasis plays a role in neurodegenerative diseases including Parkinson's disease (PD). It is known that the relative amounts of different ceramide molecular species, as defined by their fatty acyl chain length, regulate ceramide function in lipid membranes and in signaling pathways. In the present study we used a comprehensive sphingolipidomic case-control approach to determine the effects of PD on ceramide composition in postmortem brain tissue from the anterior cingulate cortex (a region with significant PD pathology) and the occipital cortex (spared in PD), also assessing mRNA expression of the major ceramide synthase genes that regulate ceramide acyl chain composition in the same tissue using quantitative PCR. In PD anterior cingulate cortex but not occipital cortex, total ceramide and sphingomyelin levels were reduced from control levels by 53% (P < 0.001) and 42% (P < 0.001), respectively. Of the 13 ceramide and 15 sphingomyelin molecular lipid species identified and quantified, there was a significant shift in the ceramide acyl chain composition toward shorter acyl chain length in the PD anterior cingulate cortex. This PD-associated change in ceramide acyl chain composition was accompanied by an upregulation of ceramide synthase-1 gene expression, which we consider may represent a response to reduced ceramide levels. These data suggest a significant shift in ceramide function in lipid membranes and signaling pathways occurs in regions with PD pathology. Identifying the regulatory mechanisms precipitating this change may provide novel targets for future therapeutics.
ABSTRACT (237/250 words)
Genetic studies have provided increasing evidence that ceramide homeostasis plays a role in neurodegenerative diseases including Parkinson's disease (PD). It is known that the relative amounts of different ceramide molecular species, as defined by their fatty acyl chain length, regulate ceramide function in lipid membranes and in signaling pathways. For this reason we used a comprehensive sphingolipidomic case-control approach to determine the effects of PD on ceramide composition in postmortem brain tissue from the anterior cingulate cortex (ACC, a region with significant PD pathology) and the occipital cortex (OCC, spared in PD), also assessing mRNA expression of the major CerS genes that regulate ceramide acyl chain composition in the same tissue using quantitative PCR. In PD ACC but not OCC, total ceramide and sphingomyelin levels were reduced from control levels by 53% (p < 0.001) and 42% (p < 0.001) respectively. Of the 13 ceramide (d18:1) and 15 sphingomyelin (d18:1) molecular lipid species identified and quantified, there was a significant shift in the ceramide acyl chain composition towards shorter acyl chain length in the PD ACC. This PD-associated change in ceramide acyl chain composition was accompanied by an upregulation of CerS1 gene expression, which we consider may represent a response to reduced ceramide levels.
These data suggest a significant shift in ceramide function in lipid membranes and signalling pathways occurs in regions with PD pathology. Identifying the regulatory mechanisms precipitating this change may provide novel targets for future therapeutics.
INTRODUCTION
Parkinson's disease (PD) is a neurodegenerative movement disorder with a prevalence of approximately 1-2% of the population over 65 years increasing to 3-5% in people over 85 years old 1, 2 . The pathological hallmarks of PD include the specific loss of dopaminergic neurons in the substantia nigra pars compacta (SN) and the formation of Lewy bodies and Lewy neurites that are composed of aggregated alpha-synuclein (α-syn) protein and other components including lipids [3] [4] [5] . Lewy pathologies occur progressively in a proportion of selective neurons located in the brainstem, temporal mesocortex and neocortex 3, [6] [7] [8] . Severe destruction of the SN and involvement of the amygdala and the anterior cingulate cortex (ACC) occur relatively early after the onset of clinical symptoms, whereas the occipital cortex is pathologically spared 3, [6] [7] [8] .
There has been a recent surge of interest in the role that altered sphingolipid homeostasis may play in neurodegenerative diseases including PD [9] [10] [11] [12] [13] [14] . Ceramide is a component of all major sphingolipid species in the brain including sphingomyelins (SMs) and glycosphingolipids (GSLs) and also plays a crucial role in regulating cellular membrane structure, in apoptosis and as a signaling molecule after its phosphorylation by ceramide kinase [15] [16] [17] [18] [19] [20] . The ceramide molecule comprises a sphingoid base to which one of several distinct fatty acid species is attached through an N-acyl linkage. The N-acylation reaction is mediated by a family of ceramide synthase (CerS) enzymes (CerS1-6) that each utilize a different restricted subset of fatty acyl CoA species 20 .
Ceramide may be generated through three main pathways (Fig 1) : (i) de novo synthesis beginning with serine and palmitoyl-CoA, (ii) via the breakdown of sphingomyelin by sphingomyelinase, and (iii) by the breakdown of glucosylceramide by glucosylceramidase (GCase) 21 . The latter route for ceramide production, also known as the salvage pathway, is the most energy efficient mechanism for ceramide generation in post-mitotic cells and is thought to account for 50% to 90% of sphingolipid production depending on the lipid molecular species and the cell type 22, 23 . Any pathological changes that impair the salvage pathway could therefore eventually have an impact on cellular membrane structure and signalling pathways [22] [23] [24] . It is highly relevant that mutations in the GBA gene (that encodes GCase) confer increased risk for PD [25] [26] [27] . Intriguingly, GCase levels and activity are reduced in several brain regions in both sporadic PD and PD cases carrying GBA mutations as compared to healthy controls 28 . In vitro studies suggest that increased α-syn levels may impair GCase trafficking and also decrease its enzyme activity 28, 29 . Overall, the prediction would be that these changes in GCase levels and/or activity would reduce cerebral ceramide levels in PD.
In the context of the function of ceramide in the brain and in neurodegenerative diseases, it is clear that it is not only the overall amount of ceramide that is important, but the relative amounts of the different ceramide molecular species as defined by their fatty acyl chain length. For example, changes in ceramide fatty acyl chain length can affect membrane order, membrane lipid peroxidation, mitochondrial function and apoptotic pathways in a distinct manner 14, [30] [31] [32] [33] . There are currently only limited data available regarding how cerebral ceramide acyl chain composition may change in PD and no data on how this may correlate with the expression of the CerS genes that control this diversity of ceramide molecular species.
In the current study we have used a sphingolipidomics case-control approach to determine the effects of PD on ceramide composition in postmortem brain tissue from the anterior cingulate cortex (ACC) and the occipital cortex (OCC). None of the cases or controls analysed in this study had known GBA mutations. The expression of the major CerS genes in the brain was also assessed at the mRNA level using quantitative PCR (qPCR).
MATERIALS AND METHODS

Materials
Methyl-tert-butyl ether (MTBE), chloroform and methanol were HPLC grade and purchased 
Sphingolipid extraction and analysis by mass spectrometry
The lipid extraction and mass spectrometry analysis was performed as previously described in detail 35 . In brief, approximately 15 mg of pulverised human brain tissue was accurately weighed directly into each 0. The lipid extracts were analysed via ESI-MS using a hybrid triple quadrupole ion trap mass spectrometer (QTRAP® 5500, AB SCIEX, Framingham, Massachusetts, USA) and an attached chip-based, automated nanospray source (Triversa Nanomate®, Advion, Ithaca, NY, USA). Sphingolipid species were quantified using AB SCIEX Lipidview™ Software (Framingham, Massachusetts, USA; see 36 ) as described previously 35 . The processing settings for Lipidview™ were: mass tolerance 0.5, minimum % intensity 0 and minimum S/N 50.
RNA extraction and ceramide synthase analysis by qPCR
The qPCR analysis of human brain samples was performed as described previously 
Statistical analyses
Statistical analyses were performed using SPSS Statistics v19.0.0 (IBM, NY, USA). All results are expressed as mean ± standard error with p < 0.05 set as the level of significance.
Group data were tested for normality using Shapiro-Wilk W test and homogeneity of variance using a 2-sided F Test. Multivariate analysis of covariance was used to assess the significance of the difference between PD and control with acyl chain structure by region as the dependent variable, case as the group variable and age and post mortem interval as covariates. The analysis of the mRNA data was conducted using a linear mixed model. To control for multiple comparisons additional post hoc comparisons were conducted using the method of Benjamini and Hochberg 39 , these analyses were conducted using the p.adjust command in the package "stats" in R version 2.15.2 (R Core Development Team) 40 .
RESULTS
Ceramide analysis
As ceramide concentration and acyl chain composition are postulated to be important in neurodegenerative diseases 9, 30 , we conducted a detailed analysis of the major ceramide molecular species in human control and PD brain samples. A quantitative (nmol/g tissue wet weight) comparison between control and PD ceramide species for grey matter samples obtained from the ACC and OCC is shown in Table 2 . A total of 13 ceramide species were detected in both regions, with fatty acyl chain lengths ranging from C16 -C26. The total ceramide concentration in the PD ACC was significantly lower (53%) than in the control ACC. Significant reductions in most individual ceramide species were observed in the PD ACC samples. The greatest reductions were detected in Cer(d18:1/22:0), Cer(d18:1/23:0) and Cer(d18:1/24:1) with approximately 60% lower levels in PD relative to control. In contrast, no significant changes in the concentration of any ceramide species were detected when the OCC samples were compared. While there were more males in the PD cohort (n = 7)
compared to the control cohort (n = 5), analysis of the sphingolipidomic mass spectrometry data for an influence of gender revealed there were no significant differences (SK Abbott and B Garner, unpublished data). The gender of the cohorts is therefore unlikely to confound the disease-status comparisons.
In order to directly compare the distribution of ceramide fatty acyl chains in the control and PD samples, the data were also expressed in units of mol % (Fig 2) . As expected 41 , by far the two most abundant ceramide species detected in both the ACC and OCC were Cer(d18:1/18:0) and Cer(d18:1/24:1). Importantly, this analysis revealed a significant increase in C18:0 acyl chain content accompanied by a significant decrease in C24:1 acyl chain content in the PD ACC compared to control ACC (Fig 2) . These changes remained significant when adjustment was made for multiple comparisons (P = 0.026 for both comparisons). This change in ceramide acyl composition was not present in the OCC sample comparison. There were additional quantitatively minor changes in acyl chain composition in the PD ACC compared to control ACC, overall indicating a shift from longer to shorter ceramide acyl chain composition in the PD cohort (Fig 2) .
Sphingomyelin analysis
We also analysed SM concentration and acyl chain composition in the same grey matter samples used for the ceramide analysis described above. Similar to the ceramide results, total SM levels were significantly decreased (42%) in the PD ACC compared to the control ACC, whereas there were no significant differences observed when the SM content of the control OCC and PD OCC were compared (Supplementary Table 1 ). When assessing SM acyl chain composition using a mol % analysis, several significant differences were revealed.
Notably, in the PD ACC significant decreases in C23:0, C24:1 and C26:1 were observed and these were accompanied by significantly increased C18:1 and C20:0 levels (and a nonsignificant trend for a 15% increase in C18:0) as compared to the control ACC. Similar to the changes in ceramide acyl chain composition, the SM data in general also suggest a shift from longer to shorter acyl chain composition in the PD cohort.
SM is present in the cellular membranes of all brain cell types, however, the vast majority of SM in the brain is within myelin. Since white matter is highly enriched in myelin, and thus myelin lipids, we conducted an additional assessment of white matter samples derived from both the ACC and OCC of control samples and PD cases. The PD-associated changes in ceramide and SM absolute amounts and acyl chain length we detected in the grey matter ACC samples were not replicated in the white matter ACC (Supplementary Table 2 
and 3).
This suggests that the grey matter ACC changes are unlikely to be due to myelin lipid changes. Interestingly, we detected a significant decrease in several white matter ceramide and SM species in the PD OCC compared to the control OCC (Supplementary Table 2 and 3).
Ceramide synthase gene expression
In order to examine a possible underlying cause of the shift from longer to shorter ceramide acyl chain composition in grey matter samples from the PD ACC cohort, we next examined grey matter samples for the expression of the 5 CerS (LASS) genes that are expressed in the human brain (CerS1, CerS2, CerS4, CerS5 and CerS6). CerS1 and CerS4 preferentially attach C18 and C20 fatty acyl chains to dihydrosphinganine to form C18 and C20 dihydroceramides. These dihydroceramides are then converted to C18 and C20 ceramides via dihydroceramide desaturase 14 . The expression of CerS1 and CerS4 mRNA was significantly increased by approximately 2-fold and 3-fold, respectively, in the PD ACC compared to the control ACC (Fig 3) . After correction for multiple comparisons the differences in CerS1 remained significant whereas the differences in CerS4 were no longer signficiant (Fig 3) . The change in ACC CerS gene expression is consistent with the PD-associated increases in C18, C20 and C16 ceramide species we detected using the sphingolipidomics analysis described above. There was no significant change in CerS2 mRNA levels in the PD ACC compared to the control ACC (Fig 3) . CerS2 is predicted to control the synthesis of C24 ceramides in the brain. It is therefore plausible that the lack of change in CerS2 accompanied by increases in CerS1 contributes to the changes in ceramide (and SM) acyl chain composition we detected in the PD ACC (Fig 2) .
In contrast to the PD-associated changes in CerS gene expression in the ACC, we did not detect an increase in CerS mRNA in the PD OCC (Fig 3) . This is again consistent with the lack of significant changes in ceramide acyl chain length in the PD OCC compared to the control OCC (Fig 2) . For reasons that remain unclear, in the PD OCC CerS5 expression was reduced. A non-significant trend for increased Cer6 expression might be predicted to result in no net change in ceramide acyl chain composition as CerS5 and CerS6 have overlapping substrate specificity (e.g. for C16 fatty acyl CoA).
Discussion
Although a strong rationale has been provided suggesting that altered ceramide metabolism may contribute to PD [9] [10] [11] [12] [13] [14] , there is very little data available regarding the molecular structure and levels of post-mortem brain ceramides in PD patients. In the present study we show that overall grey matter ceramide and SM levels are reduced in PD ACC, a brain region that contains Lewy body pathology from around Braak Stage IV onwards 3, [6] [7] [8] . In contrast, such reductions in ceramide and SM were not observed in the PD OCC, a brain region that is spared PD pathology; although in the latter case, changes in white matter sphingolipids were observed. As ceramide acyl chain structure has a major influence on the biological function of this class of lipids 14, [30] [31] [32] [33] , it is also highly significant that our data revealed for the first time a shift in ceramide acyl chain composition, with PD ACC ceramide species containing more short chain ceramides (e.g. C16:0, C18:0 and C18:1) at the expense of long chain ceramides (e.g. C23:0 and C24:1). What drives these changes cannot be determined from this (or any) post-mortem study; however, based on previous work and our current analysis of CerS mRNA expression, we provide one plausible mechanistic explanation.
As noted above, a major source of ceramide generation in the brain is thought to be via the salvage pathway. There is strong evidence that reduced GCase levels and activity are associated with PD [25] [26] [27] [28] [29] and, consistent with the data presented herein, this would be predicted to lead to a reduction in total ceramide levels in affected PD brain tissue. The abovementioned examples do not, however, provide a mechanistic explanation for the alterations in ceramide acyl chain composition that we have detected. The simplest explanation for the shift in ceramide acyl chain composition, with increased short-chain ceramides and decreased long-chain ceramides in PD, is that a homeostatic response to reductions in ceramide generated through the salvage pathway is evoked in PD. This postulated activation of de novo synthesis is supported by the selective increases in specific
CerS genes in the PD tissues that match the observed changes in ceramide acyl chain compositions. For reasons that remain to be defined, the induction of CerS gene expression in the PD ACC did not match the expression of these genes in the control brain tissues (e.g. in the PD ACC we observed a 2-fold upregulation CerS1 with no significant change in CerS2).
Regardless of the reason for the preferential induction of specific CerS genes in the PD brain, the consequent shift in ceramide acyl chain content may have physiological consequences.
Although it is tempting to speculate that the PD-associated increase in short acyl chain ceramides may promote cellular apoptosis 32 , the fact that the overall ceramide concentrations are reduced may to a degree circumvent this. A decrease in ceramide acyl chain length could also have an impact on membrane lipid order, lipid-lipid and lipid-protein interactions, signalling pathways and potentially on membrane lipid peroxidation reactions 12, 24, [46] [47] [48] . In a previous study using an independent cohort of control and PD samples we conducted a broad liquid chromatography -mass spectrometry (LC-MS) lipidomics analysis of late stage (7/10 PD cases were Braak stage V) PD ACC samples 37 . In this earlier analysis we were able to accurately quantify 6 Cer(d18:1) molecular species. Interestingly, this earlier study also Values expressed as mean ± SE. P values represent the effect of group from multivariate analysis of covariance with region as the within subject factor and age and postmortem interval as covariates. * Indicates p value is still significant at the 0.05 level when further post hoc adjustment is done for the 26 individual comparisons using the Benjamini and Hochberg approach. Values expressed as mean ± SE. P values represent the effect of group from multivariate analysis of covariance with region as the within subject factor and age and postmortem interval as covariates. * Indicates p value is still significant at the 0.05 level when further post hoc adjustment is done for the 26 individual comparisons using the Benjamini and Hochberg approach. 
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